The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-fos signaling axis

Takashi Izawa, Rieko Arakaki, Hiroki Mori, Takaaki Tsunematsu, Yasusei Kudo, Eiji Tanaka, Naozumi Ishimaru

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aryl hydrocarbon receptor (AhR) pathway plays a key role in receptor activator of NF-κB ligand (RANKL)-mediated osteoclastogenesis. However, the mechanism underlying the regulation of AhR expression in osteoclasts and the signaling pathway through which AhR controls osteoclastogenesis remain unclear. We found that the expression of AhR in bone marrow-derived osteoclasts was upregulated by RANKL at an earlier stage than was the expression of signature osteoclast genes such as those encoding cathepsin K and NFAT, cytoplasmic, calcineurin-dependent 1. In response to RANKL, bone marrow macrophages isolated from AhR-/- mice exhibited impaired phosphorylation of Akt and MAPK as well as NF-κB, whereas their response to M-CSF remained unchanged. Osteoclast differentiation mediated by the AhR signaling pathway was also regulated in an RANKL/c-Fos-dependent manner. Furthermore, ligand activation of AhR by the smoke toxin benzo[a]pyrene accelerated osteoclast differentiation in a receptor-dependent manner, and AhR-dependent regulation of mitochondrial biogenesis in osteoclasts was observed. Moreover, AhR-/- mice exhibited impaired bone healing with delayed endochondral ossification. Taken together, the present results suggest that the RANKL/AhR/c-Fos signaling axis plays a critical role in osteoclastogenesis, thereby identifying the potential of AhR in treating pathological, inflammatory, or metabolic disorders of the bone.

Original languageEnglish
Pages (from-to)4639-4650
Number of pages12
JournalJournal of Immunology
Volume197
Issue number12
DOIs
Publication statusPublished - Dec 15 2016
Externally publishedYes

Fingerprint

Aryl Hydrocarbon Receptors
Osteoclasts
Cytoplasmic and Nuclear Receptors
Homeostasis
Bone and Bones
Osteogenesis
Bone Marrow
Cathepsin K
Ligands
Macrophage Colony-Stimulating Factor
Calcineurin
Benzo(a)pyrene
Organelle Biogenesis
Transcriptome
Smoke
Macrophages
Phosphorylation

ASJC Scopus subject areas

  • Immunology

Cite this

The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-fos signaling axis. / Izawa, Takashi; Arakaki, Rieko; Mori, Hiroki; Tsunematsu, Takaaki; Kudo, Yasusei; Tanaka, Eiji; Ishimaru, Naozumi.

In: Journal of Immunology, Vol. 197, No. 12, 15.12.2016, p. 4639-4650.

Research output: Contribution to journalArticle

Izawa, Takashi ; Arakaki, Rieko ; Mori, Hiroki ; Tsunematsu, Takaaki ; Kudo, Yasusei ; Tanaka, Eiji ; Ishimaru, Naozumi. / The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-fos signaling axis. In: Journal of Immunology. 2016 ; Vol. 197, No. 12. pp. 4639-4650.
@article{14f576ce23e04415bc52fe413bc63c40,
title = "The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-fos signaling axis",
abstract = "The aryl hydrocarbon receptor (AhR) pathway plays a key role in receptor activator of NF-κB ligand (RANKL)-mediated osteoclastogenesis. However, the mechanism underlying the regulation of AhR expression in osteoclasts and the signaling pathway through which AhR controls osteoclastogenesis remain unclear. We found that the expression of AhR in bone marrow-derived osteoclasts was upregulated by RANKL at an earlier stage than was the expression of signature osteoclast genes such as those encoding cathepsin K and NFAT, cytoplasmic, calcineurin-dependent 1. In response to RANKL, bone marrow macrophages isolated from AhR-/- mice exhibited impaired phosphorylation of Akt and MAPK as well as NF-κB, whereas their response to M-CSF remained unchanged. Osteoclast differentiation mediated by the AhR signaling pathway was also regulated in an RANKL/c-Fos-dependent manner. Furthermore, ligand activation of AhR by the smoke toxin benzo[a]pyrene accelerated osteoclast differentiation in a receptor-dependent manner, and AhR-dependent regulation of mitochondrial biogenesis in osteoclasts was observed. Moreover, AhR-/- mice exhibited impaired bone healing with delayed endochondral ossification. Taken together, the present results suggest that the RANKL/AhR/c-Fos signaling axis plays a critical role in osteoclastogenesis, thereby identifying the potential of AhR in treating pathological, inflammatory, or metabolic disorders of the bone.",
author = "Takashi Izawa and Rieko Arakaki and Hiroki Mori and Takaaki Tsunematsu and Yasusei Kudo and Eiji Tanaka and Naozumi Ishimaru",
year = "2016",
month = "12",
day = "15",
doi = "10.4049/jimmunol.1600822",
language = "English",
volume = "197",
pages = "4639--4650",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - The nuclear receptor AhR controls bone homeostasis by regulating osteoclast differentiation via the RANK/c-fos signaling axis

AU - Izawa, Takashi

AU - Arakaki, Rieko

AU - Mori, Hiroki

AU - Tsunematsu, Takaaki

AU - Kudo, Yasusei

AU - Tanaka, Eiji

AU - Ishimaru, Naozumi

PY - 2016/12/15

Y1 - 2016/12/15

N2 - The aryl hydrocarbon receptor (AhR) pathway plays a key role in receptor activator of NF-κB ligand (RANKL)-mediated osteoclastogenesis. However, the mechanism underlying the regulation of AhR expression in osteoclasts and the signaling pathway through which AhR controls osteoclastogenesis remain unclear. We found that the expression of AhR in bone marrow-derived osteoclasts was upregulated by RANKL at an earlier stage than was the expression of signature osteoclast genes such as those encoding cathepsin K and NFAT, cytoplasmic, calcineurin-dependent 1. In response to RANKL, bone marrow macrophages isolated from AhR-/- mice exhibited impaired phosphorylation of Akt and MAPK as well as NF-κB, whereas their response to M-CSF remained unchanged. Osteoclast differentiation mediated by the AhR signaling pathway was also regulated in an RANKL/c-Fos-dependent manner. Furthermore, ligand activation of AhR by the smoke toxin benzo[a]pyrene accelerated osteoclast differentiation in a receptor-dependent manner, and AhR-dependent regulation of mitochondrial biogenesis in osteoclasts was observed. Moreover, AhR-/- mice exhibited impaired bone healing with delayed endochondral ossification. Taken together, the present results suggest that the RANKL/AhR/c-Fos signaling axis plays a critical role in osteoclastogenesis, thereby identifying the potential of AhR in treating pathological, inflammatory, or metabolic disorders of the bone.

AB - The aryl hydrocarbon receptor (AhR) pathway plays a key role in receptor activator of NF-κB ligand (RANKL)-mediated osteoclastogenesis. However, the mechanism underlying the regulation of AhR expression in osteoclasts and the signaling pathway through which AhR controls osteoclastogenesis remain unclear. We found that the expression of AhR in bone marrow-derived osteoclasts was upregulated by RANKL at an earlier stage than was the expression of signature osteoclast genes such as those encoding cathepsin K and NFAT, cytoplasmic, calcineurin-dependent 1. In response to RANKL, bone marrow macrophages isolated from AhR-/- mice exhibited impaired phosphorylation of Akt and MAPK as well as NF-κB, whereas their response to M-CSF remained unchanged. Osteoclast differentiation mediated by the AhR signaling pathway was also regulated in an RANKL/c-Fos-dependent manner. Furthermore, ligand activation of AhR by the smoke toxin benzo[a]pyrene accelerated osteoclast differentiation in a receptor-dependent manner, and AhR-dependent regulation of mitochondrial biogenesis in osteoclasts was observed. Moreover, AhR-/- mice exhibited impaired bone healing with delayed endochondral ossification. Taken together, the present results suggest that the RANKL/AhR/c-Fos signaling axis plays a critical role in osteoclastogenesis, thereby identifying the potential of AhR in treating pathological, inflammatory, or metabolic disorders of the bone.

UR - http://www.scopus.com/inward/record.url?scp=85002180250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002180250&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1600822

DO - 10.4049/jimmunol.1600822

M3 - Article

C2 - 27849171

AN - SCOPUS:85002180250

VL - 197

SP - 4639

EP - 4650

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -